The Russian direct investment Fund (RDIF) and a group of companies “Chemrar” announced the receipt of a positive first interim results of a multicenter randomized comparative open clinical study of the drug favipiravir, which takes place in patients hospitalized with COVID-19.
According to the data collected, 60% of patients (from 40 participants) receiving favipiravir had a negative test for the coronavirus after 5 days of therapy. This figure was 2 times higher than in the group of standard therapy. The data coincide with the results of the Chinese studies that also showed reduction in the duration of the disease from 11 days to 4-5 days.
The next important step is obtaining a registration certificate on possibility of application of favipiravir in the entire country, then the group of companies “Chemrar” in cooperation with the RDIF can start commercial supplies of the drug at the end of may.
To date have produced 250 courses of the drug, another 1,500 courses in stage production, said the CEO of RDIF Kirill Dmitriev. He said that together with GK “Khimrar” established technological lines for production of up to 600,000 courses a year.